Status:
COMPLETED
Long-term Data Collection for Subjects in MDX-010 Studies
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.
Detailed Description
This is a multicenter, follow-up study in up to 191 subjects with metastatic melanoma who were previously enrolled and treated in ipilimumab studies MDX010-02, MDX010-08, and MDX010-15. The purpose of...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15.
- Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained.
- For subjects who have died or have been lost to follow-up(the subject status at end of original ipilimumab study), approval from the appropriate site IRB, specifying or limiting appropriate means for obtaining information, must be granted prior to collection of any information.
Exclusion
Key Trial Info
Start Date :
June 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00928031
Start Date
June 1 2007
End Date
April 1 2009
Last Update
April 26 2010
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Cancer Center
Tuscon, Arizona, United States, 85724
2
Pacific Shores Medical Group
Long Beach, California, United States, 90813
3
The Angeles Clinic and Research Institute
Los Angeles, California, United States, 90025
4
USC Norris Cancer Center
Los Angeles, California, United States, 90033